Abstract
A case report of a patient with agranulocytosis associated with sulphasalazine therapy is described. Recovery followed supportive therapy and withdrawal of the drug. Investigations including tests for leucocyte antibodies, the presence of which might have suggested an immunological cause for the drug reaction, were negative; an acetylation study, however, characterized the patient as a ‘slow’ acetylator phenotype, suggesting that the drug reaction was more likely to have been toxic in nature. It is suggested that acetylation studies be performed in patients who have previously shown serious side effects to sulphasalazine to assess the incidence of ‘slow’ acetylators.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BOETTIGER L. E., ENGSTEDT L., LAGERCRANTZ R., NYBERG A. THE OCCURRENCE OF HEINZ BODIES DURING AZULFIDINE TREATMENT OF ULCERATIVE COLITIS. Gastroenterologia. 1963;100:33–41. doi: 10.1159/000202343. [DOI] [PubMed] [Google Scholar]
- Collins J. R. Adverse reactions to salicylazosulfapyridine (azulfidine) in the treatment of ulcerative colitis. South Med J. 1968 Apr;61(4):354–358. doi: 10.1097/00007611-196804000-00005. [DOI] [PubMed] [Google Scholar]
- EVANS D. A., WHITE T. A. HUMAN ACETYLATION POLYMORPHISM. J Lab Clin Med. 1964 Mar;63:394–403. [PubMed] [Google Scholar]
- EVANS R. S., FORD W. P., Jr Studies of the bone marrow in immunological granulocytopenia; following administration of salicylazosulfapyridine. AMA Arch Intern Med. 1958 Feb;101(2):244–251. doi: 10.1001/archinte.1958.00260140076012. [DOI] [PubMed] [Google Scholar]
- GARDNER M. D., BARGEN J. A. HEMOLYTIC ANEMIA SECONDARY TO SALICYLAZOSULFAPYRIDINE THERAPY. JAMA. 1964 Oct 5;190:71–72. [PubMed] [Google Scholar]
- LENNARD-JONES J. E., LONGMORE A. J., NEWELL A. C., WILSON C. W., JONES F. A. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut. 1960 Sep;1:217–222. doi: 10.1136/gut.1.3.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schröder H., Evans D. A. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut. 1972 Apr;13(4):278–284. doi: 10.1136/gut.13.4.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schröder H. Simplified method for determining acetylator phenotype. Br Med J. 1972 Aug 26;3(5825):506–507. doi: 10.1136/bmj.3.5825.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
- THIRKETTLE J. L., GOUGH K. R., READ A. E. Agranulocytosis associated with sulphasalazine ('Salazopyrin') therapy. Lancet. 1963 Jun 29;1(7296):1395–1397. doi: 10.1016/s0140-6736(63)92048-8. [DOI] [PubMed] [Google Scholar]